skip to content

GW Pharmaceuticals

18:15 on 08/12/2016

Current Price 725.50p | Bid 0.00p | Ask 0.00p | Change 0.00%

Company Overview

GW Pharmaceuticals PLC is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of non-smoked prescription medicines derived from cannabis, including Sativex®, to meet patient needs in a wide range of therapeutic indications. The Group has also expanded its research to include the use of other controlled drugs in conjunction with its proprietary secure drug dispensing technology. GW's lead product, Sativex®, was approved by Health Canada in April 2005 for the relief of neuropathic pain in Multiple Sclerosis (MS) and was launched in Canada in June 2005 by Bayer HealthCare who will exclusively market Sativex® in Canada. GW maintains control over all aspects of the product development process - botanical research, cultivation, extraction, formulation into drug delivery technologies, clinical trials and regulatory affairs. With a view to encouraging exploratory research and identifying future product opportunities, GW established in March 2002 a separate division called the Cannabinoid Research Institute or 'CRI'. The CRI aims to link industry and academia in conducting exploratory research which it is hoped will lead to the identification of new indications for cannabis-based medicines and greater understanding of the mechanism of action of cannabinoids. GW has also developed a novel, secure and tamper-proof means of dispensing drugs. The technology is called the Advanced Dispensing System (ADS) and provides high levels of security for dispensing drugs, whilst also enabling clinicians to remotely monitor and, if required, remotely control drug usage in real time. In October 2003, ADS won the AiM Stock Exchange 'Best Technology' Award.

Stock Details

ISIN GB0030544687
Shares in Issue 301,770,915
Market cap £2,064.11m
Sector Pharmaceuticals & Biotechnology
Indices FTSE AIM All-Share Index

Financial Highlights Year Ended 30/09/2015

Turnover $43.17 million
Operating Profit $-86.57 million
Dividend Yield 0.00
Dividend Per Share 0.00
Dividend Cover 0.00
P/E Ratio -24.96
» More Financials

Key Personnel

David Kirk Finance Director

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Price Summary

Mid Price ? 0.00p
Bid Price ? 0.00p
Ask Price ? 0.00p
Volume ? 0
Change Today 0.00p
% Change Today 0.00%
Open 0.00p
Previous Close 735.00p
Intraday High 0.00p
Intraday Low 0.00p
52 Week High 698.25p
52 Week Low 211.00p

Intra-Day Chart

More Charts »

Broker Consensus

The above information represents a selection of the views and target prices published in the last 120 days by analysts in individual stocks. It is subject to change without notice and may not necessarily be the view held by Redmayne-Bentley.

Client Area Access

» Secure Login

» Not registered yet?

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.